Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion

Inclusion Criteria: For inclusion in the study subjects should fulfill the following criteria: * Provision of informed consent prior to any study specific procedures * Males and females aged 19 years and older * Congruent to the PLATO trial, at least two of the following three criteria have to be met: * ST-segment changes on electrocardiography, indicating ischemia; (In electrocardiography, the ST segment connects the QRS complex and the T wave and has a duration of 0.080 to 0.120 sec (80 to 120 ms). * a positive test of a biomarker, indicating myocardial necrosis; or one of several risk factors; * age \>60 years * previous myocardial infarction or Coronary-Artery Bypass Grafting \[CABG\]; * coronary artery disease with stenosis of ≥50% in at least two vessels; * previous ischemic stroke, transient ischemic attack, carotid stenosis of at least 50%, or cerebral revascularization; * diabetes mellitus; * peripheral arterial disease; * or chronic renal dysfunction, defined as a creatinine clearance of \<60 ml per minute per 1.73 m2 of body surface area). * patients with symptoms of unstable angina lasting ≥10 min and either an elevated troponin I level or newly developed ST-segment depression of 1 mm or transient ST-segment elevation of 1 mm will also be included. Exclusion Criteria: Subjects should not enter the study if any of the following exclusion criteria are fulfilled: * Patients with active pathological bleeding or a history of intracranial bleeding; * patients with planned to urgent coronary artery bypass graft surgery; * severe hepatic impairment; * concomitant therapy with a strong cytochrome P-450 3A inhibitors, where 3A is s subfamily of the cytochrome P450 superfamily of genes; * surgery\<4 weeks; * the use of any thienopyridine (within the previous two weeks); * upstream use of Glycoprotein (GP) IIb/IIIa inhibitors; * bleeding diathesis or major bleeding episode within 2 weeks; * a need for oral anticoagulation therapy; * thrombocytopenia; * presence of thrombus in the coronary artery; incessant chest pain or hemodynamic instability; * and patients with glomerular filtration rate (GFR)\<30 mL/min or on hemodialysis. * maintenance dose of aspirin above 100mg * history of allergies to Ticagrelor * patients at increased risk of bradycardic events (e.g., patients who have sick sinus syndrome, 2nd or 3rd degree Atrioventricular block (AV block), or bradycardic related syncope and not protected with a pacemaker * women who are pregnant or breastfeeding